melatonin has been researched along with Angiogenesis, Pathologic in 33 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| " To reach the search formula, we determined mean key words like breast cancer, melatonin, cell proliferation and death." | 8.95 | Melatonin, an inhibitory agent in breast cancer. ( Akbari, ME; Bashash, D; Nooshinfar, E; Safaroghli-Azar, A, 2017) |
| "Apatinib or a combination of Apatinib/melatonin may be used to manage patients with breast cancer." | 8.12 | Effect of Apatinib plus melatonin on vasculogenic mimicry formation by cancer stem cells from breast cancer cell line. ( Akbarzadeh, M; Isazadeh, A; Jahanbazi, R; Kazemzadeh, H; Maroufi, NF; Mostafaei, S; Nejabati, HR; Nouri, M; Rashidi, M; Rashidi, MR; Vahedian, V, 2022) |
| "Melatonin is recognized as an anti-angiogenic agent, but its function in the tumor microenvironment especially in osteosarcoma remains uncertain." | 7.96 | Melatonin regulates tumor angiogenesis via miR-424-5p/VEGFA signaling pathway in osteosarcoma. ( Anuradha, D; Raghunandhakumar, S; Saravanan, S; Vimalraj, S, 2020) |
| "The aim of this study was to evaluate the role of melatonin and the tumor suppressor miR- 148a-3p on angiogenesis of breast cancer." | 7.91 | Therapeutic Potential of Melatonin in the Regulation of MiR-148a-3p and Angiogenic Factors in Breast Cancer. ( Aristizábal-Pachón, AF; Bajgelman, MC; Borin, TF; Ferreira, LC; Lacerda, JZ; Lopes, BC; Zuccari, DAPC, 2019) |
| "Hypoxia has an important role in tumor progression via the up-regulation of growth factors and cellular adaptation genes." | 6.72 | Melatonin as a Therapeutic Agent for the Inhibition of Hypoxia-Induced Tumor Progression: A Description of Possible Mechanisms Involved. ( Akbarzadeh, M; Bastani, S; Farzane, A; Fattahi, A; Mollapour Sisakht, M; Nouri, M; Rastgar Rezaei, Y; Reiter, RJ, 2021) |
| "Breast cancer is the most common cancer among women and its metastasis which generally observed at the last stage is the major cause of breast cancer-related death." | 6.66 | The potential therapeutic effects of melatonin on breast cancer: An invasion and metastasis inhibitor. ( Akbarzadeh, M; Amirzadeh-Iranaq, MT; Ashoori, Z; Ashouri, N; Bizzarri, M; Faridvand, Y; Fattahi, A; Kazemzadeh, H; Maroufi, NF; Mortezania, Z; Nejabati, HR; Nouri, M; Rashidi, MR; Vahedian, V, 2020) |
| "Melatonin in vitro treatment (1 mM) decreased cell viability (p<0." | 5.40 | Effect of melatonin on tumor growth and angiogenesis in xenograft model of breast cancer. ( Ali, MM; Arbab, AS; Borin, TF; de Campos Zuccari, DA; Ferreira, LC; Iskander, AS; Jardim-Perassi, BV; Shankar, A; Varma, NR, 2014) |
| " To reach the search formula, we determined mean key words like breast cancer, melatonin, cell proliferation and death." | 4.95 | Melatonin, an inhibitory agent in breast cancer. ( Akbari, ME; Bashash, D; Nooshinfar, E; Safaroghli-Azar, A, 2017) |
| "Apatinib or a combination of Apatinib/melatonin may be used to manage patients with breast cancer." | 4.12 | Effect of Apatinib plus melatonin on vasculogenic mimicry formation by cancer stem cells from breast cancer cell line. ( Akbarzadeh, M; Isazadeh, A; Jahanbazi, R; Kazemzadeh, H; Maroufi, NF; Mostafaei, S; Nejabati, HR; Nouri, M; Rashidi, M; Rashidi, MR; Vahedian, V, 2022) |
| " The aim of this study was to evaluate a combination consisting of a ketogenic diet and melatonin to determine whether it would inhibit cisplatin- and vincristine-resistant breast cancer." | 3.96 | A ketogenic diet combined with melatonin overcomes cisplatin and vincristine drug resistance in breast carcinoma syngraft. ( Talib, WH, 2020) |
| "Melatonin is recognized as an anti-angiogenic agent, but its function in the tumor microenvironment especially in osteosarcoma remains uncertain." | 3.96 | Melatonin regulates tumor angiogenesis via miR-424-5p/VEGFA signaling pathway in osteosarcoma. ( Anuradha, D; Raghunandhakumar, S; Saravanan, S; Vimalraj, S, 2020) |
| "The aim of this study was to evaluate the role of melatonin and the tumor suppressor miR- 148a-3p on angiogenesis of breast cancer." | 3.91 | Therapeutic Potential of Melatonin in the Regulation of MiR-148a-3p and Angiogenic Factors in Breast Cancer. ( Aristizábal-Pachón, AF; Bajgelman, MC; Borin, TF; Ferreira, LC; Lacerda, JZ; Lopes, BC; Zuccari, DAPC, 2019) |
| "The objectives of this study were to determine the effectiveness of melatonin in cell viability and expression of proteins involved in angiogenesis and inflammation in triplenegative mammary tumor cell line (MDA-MB-231) and in co-culture with CAFs." | 3.83 | Melatonin Regulates Angiogenic and Inflammatory Proteins in MDA-MB-231 Cell Line and in Co-culture with Cancer-associated Fibroblasts. ( Bordin, NA; Borin, TF; Cardoso, JP; Corrêa, LA; Gelaleti, GB; Jardim-Perassi, BV; Lacerda, JZ; Lopes, JR; Maschio-Signorini, LB; Moschetta, MG; Roela, RA; Zuccari, DA, 2016) |
| "Hypoxia has an important role in tumor progression via the up-regulation of growth factors and cellular adaptation genes." | 2.72 | Melatonin as a Therapeutic Agent for the Inhibition of Hypoxia-Induced Tumor Progression: A Description of Possible Mechanisms Involved. ( Akbarzadeh, M; Bastani, S; Farzane, A; Fattahi, A; Mollapour Sisakht, M; Nouri, M; Rastgar Rezaei, Y; Reiter, RJ, 2021) |
| "Melatonin has a variety of biological effects, including inhibition of tumor metastasis, stabilizing atherosclerotic plaques, and the regulation of seasonal reproductive rhythms, etc." | 2.66 | Role of melatonin in controlling angiogenesis under physiological and pathological conditions. ( Chen, Y; Ma, Q; Reiter, RJ, 2020) |
| "Breast cancer is the most common cancer among women and its metastasis which generally observed at the last stage is the major cause of breast cancer-related death." | 2.66 | The potential therapeutic effects of melatonin on breast cancer: An invasion and metastasis inhibitor. ( Akbarzadeh, M; Amirzadeh-Iranaq, MT; Ashoori, Z; Ashouri, N; Bizzarri, M; Faridvand, Y; Fattahi, A; Kazemzadeh, H; Maroufi, NF; Mortezania, Z; Nejabati, HR; Nouri, M; Rashidi, MR; Vahedian, V, 2020) |
| "Melatonin is a natural indoleamine produced by the pineal gland that has many functions, including regulation of the circadian rhythm." | 2.58 | Melatonin and Cancer Hallmarks. ( Talib, WH, 2018) |
| "Melatonin is a pleiotropic anti-cancer molecule that affects malignant cells via multiple mechanisms." | 2.55 | Melatonin as a multifunctional anti-cancer molecule: Implications in gastric cancer. ( Abdollahi, M; Asghari, MH; Fallah, M; Ghobadi, E; Moloudizargari, M, 2017) |
| "Gastrointestinal cancer is a disease that affects the population worldwide with high morbidity and mortality." | 2.52 | Melatonin as a treatment for gastrointestinal cancer: a review. ( Di, S; Fan, C; Ji, G; Jiang, P; Jiang, S; Reiter, RJ; Wu, G; Xin, Z; Yan, X; Yang, Y, 2015) |
| "Melatonin is a molecule with different antitumor actions in breast cancer and has been described as an inhibitor of vascular endothelial growth factor (VEGF)." | 1.91 | Development of in vitro and in vivo tools to evaluate the antiangiogenic potential of melatonin to neutralize the angiogenic effects of VEGF and breast cancer cells: CAM assay and 3D endothelial cell spheroids. ( Alba, E; Aranega-Martín, L; Boutriq, S; Castellano-Castillo, D; González-González, A; Laborda-Illanes, A; Peralta-Linero, J; Plaza-Andrades, I; Queipo-Ortuño, MI; Sánchez-Alcoholado, L, 2023) |
| "Melatonin-treated animals showed a significant reduction in OC size and microvessel density." | 1.46 | Melatonin Reduces Angiogenesis in Serous Papillary Ovarian Carcinoma of Ethanol-Preferring Rats. ( Camargo, IC; Chuffa, LG; Domeniconi, RF; Lupi Júnior, LA; Martinez, FE; Martinez, M; Pinheiro, PF; Reiter, RJ; Zonta, YR, 2017) |
| "Melatonin in vitro treatment (1 mM) decreased cell viability (p<0." | 1.40 | Effect of melatonin on tumor growth and angiogenesis in xenograft model of breast cancer. ( Ali, MM; Arbab, AS; Borin, TF; de Campos Zuccari, DA; Ferreira, LC; Iskander, AS; Jardim-Perassi, BV; Shankar, A; Varma, NR, 2014) |
| "Treatment with melatonin did not demonstrate inhibition of the expression of genes HIF-1α, VEGF and ROCK-1 in line SCC25, which has different molecular characteristics and greater degree of malignancy when compared to the line SCC9." | 1.40 | Molecular markers of angiogenesis and metastasis in lines of oral carcinoma after treatment with melatonin. ( Colombo, J; Goncalves, Ndo N; Jardim-Perassi, BV; Lopes, JR; Moschetta, MG; Rodrigues, RV; Zuccari, DA, 2014) |
| "In this study, we used human HepG2 liver cancer cells as an in vitro model to investigate the anti-angiogenic effects of melatonin." | 1.39 | Inhibition of VEGF expression through blockade of Hif1α and STAT3 signalling mediates the anti-angiogenic effect of melatonin in HepG2 liver cancer cells. ( Benet, M; Carbajo-Pescador, S; García-Palomo, A; González-Gallego, J; Jover, R; Mauriz, JL; Ordoñez, R, 2013) |
| "Melatonin is an important natural oncostatic agent, and our previous studies have found its inhibitory action on tumor angiogenesis, but the mechanism remains unclear." | 1.38 | Melatonin prevents human pancreatic carcinoma cell PANC-1-induced human umbilical vein endothelial cell proliferation and migration by inhibiting vascular endothelial growth factor expression. ( Cui, P; Dong, L; Peng, X; Yang, Z; Yu, M, 2012) |
| "Sphingosine kinase 1 (SPHK1) is a newly discovered modulator of hypoxia inducible factor 1α (HIF-1α) with various biological activities such as cell growth, survival, invasion, angiogenesis, and carcinogenesis." | 1.37 | Sphingosine kinase 1 pathway is involved in melatonin-induced HIF-1α inactivation in hypoxic PC-3 prostate cancer cells. ( Chen, CY; Cho, SY; Jeong, SJ; Kim, HS; Kim, SH; Lee, EO; Lee, HJ, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (3.03) | 29.6817 |
| 2010's | 23 (69.70) | 24.3611 |
| 2020's | 9 (27.27) | 2.80 |
| Authors | Studies |
|---|---|
| Bastani, S | 1 |
| Akbarzadeh, M | 5 |
| Rastgar Rezaei, Y | 1 |
| Farzane, A | 1 |
| Nouri, M | 4 |
| Mollapour Sisakht, M | 1 |
| Fattahi, A | 2 |
| Reiter, RJ | 4 |
| Maroufi, NF | 3 |
| Rashidi, M | 1 |
| Vahedian, V | 3 |
| Jahanbazi, R | 1 |
| Mostafaei, S | 1 |
| Kazemzadeh, H | 2 |
| Nejabati, HR | 2 |
| Isazadeh, A | 1 |
| Rashidi, MR | 3 |
| Laborda-Illanes, A | 3 |
| Sánchez-Alcoholado, L | 3 |
| Castellano-Castillo, D | 3 |
| Boutriq, S | 3 |
| Plaza-Andrades, I | 3 |
| Aranega-Martín, L | 3 |
| Peralta-Linero, J | 3 |
| Alba, E | 3 |
| González-González, A | 4 |
| Queipo-Ortuño, MI | 3 |
| Wu, H | 1 |
| Liu, J | 1 |
| Yin, Y | 1 |
| Zhang, D | 1 |
| Xia, P | 1 |
| Zhu, G | 1 |
| Ma, Q | 1 |
| Chen, Y | 1 |
| Talib, WH | 2 |
| González, A | 1 |
| Rueda, N | 1 |
| Alonso-González, C | 1 |
| Menéndez, JM | 1 |
| Martínez-Campa, C | 1 |
| Mitola, S | 1 |
| Cos, S | 1 |
| Amiri, M | 1 |
| Dizaji, BF | 1 |
| Roshanravan, N | 1 |
| Haiaty, S | 1 |
| Vimalraj, S | 1 |
| Saravanan, S | 1 |
| Raghunandhakumar, S | 1 |
| Anuradha, D | 1 |
| Ashouri, N | 1 |
| Mortezania, Z | 1 |
| Ashoori, Z | 1 |
| Amirzadeh-Iranaq, MT | 1 |
| Bizzarri, M | 1 |
| Faridvand, Y | 1 |
| Zonta, YR | 1 |
| Martinez, M | 1 |
| Camargo, IC | 1 |
| Domeniconi, RF | 1 |
| Lupi Júnior, LA | 1 |
| Pinheiro, PF | 1 |
| Martinez, FE | 1 |
| Chuffa, LG | 1 |
| Kumari, R | 1 |
| Rawat, K | 1 |
| Kumari, A | 1 |
| Shrivastava, A | 1 |
| Gelaleti, GB | 3 |
| Borin, TF | 5 |
| Maschio-Signorini, LB | 2 |
| Moschetta, MG | 4 |
| Jardim-Perassi, BV | 5 |
| Calvinho, GB | 1 |
| Facchini, MC | 1 |
| Viloria-Petit, AM | 1 |
| de Campos Zuccari, DAP | 1 |
| Asghari, MH | 2 |
| Moloudizargari, M | 2 |
| Ghobadi, E | 1 |
| Fallah, M | 1 |
| Abdollahi, M | 2 |
| Goradel, NH | 1 |
| Negahdari, B | 1 |
| Haghi-Aminjan, H | 1 |
| Ehrlich, L | 1 |
| Scrushy, M | 1 |
| Meng, F | 1 |
| Lairmore, TC | 1 |
| Alpini, G | 1 |
| Glaser, S | 1 |
| Marques, JHM | 1 |
| Mota, AL | 1 |
| Oliveira, JG | 1 |
| Lacerda, JZ | 3 |
| Stefani, JP | 1 |
| Ferreira, LC | 4 |
| Castro, TB | 1 |
| Aristizábal-Pachón, AF | 2 |
| Zuccari, DAPC | 2 |
| Lopes, BC | 1 |
| Bajgelman, MC | 1 |
| Doğanlar, ZB | 1 |
| Güçlü, H | 1 |
| Öztopuz, Ö | 1 |
| Türkön, H | 1 |
| Dogan, A | 1 |
| Uzun, M | 1 |
| Doğanlar, O | 1 |
| Carbajo-Pescador, S | 1 |
| Ordoñez, R | 1 |
| Benet, M | 1 |
| Jover, R | 1 |
| García-Palomo, A | 1 |
| Mauriz, JL | 1 |
| González-Gallego, J | 1 |
| Arbab, AS | 1 |
| Varma, NR | 1 |
| Iskander, AS | 1 |
| Shankar, A | 1 |
| Ali, MM | 1 |
| de Campos Zuccari, DA | 1 |
| Goncalves, Ndo N | 1 |
| Rodrigues, RV | 1 |
| Lopes, JR | 2 |
| Colombo, J | 1 |
| Zuccari, DA | 2 |
| Xin, Z | 1 |
| Jiang, S | 1 |
| Jiang, P | 1 |
| Yan, X | 1 |
| Fan, C | 1 |
| Di, S | 1 |
| Wu, G | 1 |
| Yang, Y | 1 |
| Ji, G | 1 |
| Lourenço, MR | 1 |
| Doho, GM | 1 |
| Grígolo, IH | 1 |
| Pires de Campos Zuccari, DA | 1 |
| Nooshinfar, E | 1 |
| Safaroghli-Azar, A | 1 |
| Bashash, D | 1 |
| Akbari, ME | 1 |
| Roela, RA | 1 |
| Bordin, NA | 1 |
| Corrêa, LA | 1 |
| Cardoso, JP | 1 |
| Park, SY | 1 |
| Jang, WJ | 1 |
| Yi, EY | 1 |
| Jang, JY | 1 |
| Jung, Y | 1 |
| Jeong, JW | 2 |
| Kim, YJ | 1 |
| Cho, SY | 1 |
| Lee, HJ | 2 |
| Jeong, SJ | 1 |
| Kim, HS | 1 |
| Chen, CY | 1 |
| Lee, EO | 1 |
| Kim, SH | 1 |
| Iamshanov, VA | 1 |
| Cui, P | 1 |
| Yu, M | 1 |
| Peng, X | 1 |
| Dong, L | 1 |
| Yang, Z | 1 |
| Kim, KJ | 1 |
| Choi, JS | 1 |
| Kang, I | 1 |
| Kim, KW | 1 |
| Jeong, CH | 1 |
| Mias, C | 1 |
| Trouche, E | 1 |
| Seguelas, MH | 1 |
| Calcagno, F | 1 |
| Dignat-George, F | 1 |
| Sabatier, F | 1 |
| Piercecchi-Marti, MD | 1 |
| Daniel, L | 1 |
| Bianchi, P | 1 |
| Calise, D | 1 |
| Bourin, P | 1 |
| Parini, A | 1 |
| Cussac, D | 1 |
10 reviews available for melatonin and Angiogenesis, Pathologic
| Article | Year |
|---|---|
Melatonin as a Therapeutic Agent for the Inhibition of Hypoxia-Induced Tumor Progression: A Description of Possible Mechanisms Involved.
Topics: Animals; Apoptosis; Cell Movement; Cell Proliferation; Humans; Hypoxia; Melatonin; Neoplasms; Neovas | 2021 |
Therapeutic Opportunities in Colorectal Cancer: Focus on Melatonin Antioncogenic Action.
Topics: Apoptosis; Autophagy; Cell Proliferation; Circadian Rhythm; Colorectal Neoplasms; Gastrointestinal T | 2019 |
Role of melatonin in controlling angiogenesis under physiological and pathological conditions.
Topics: Animals; Cell Differentiation; Cell Movement; Cell Proliferation; Endothelial Cells; Humans; Melaton | 2020 |
The potential therapeutic effects of melatonin on breast cancer: An invasion and metastasis inhibitor.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Proliferation; Humans; Melatonin; Neoplastic Processes | 2020 |
Melatonin as a multifunctional anti-cancer molecule: Implications in gastric cancer.
Topics: Animals; Antineoplastic Agents; Humans; Melatonin; Neoplasm Metastasis; Neovascularization, Patholog | 2017 |
Melatonin as an angiogenesis inhibitor to combat cancer: Mechanistic evidence.
Topics: Angiogenesis Inhibitors; Angiogenic Proteins; Animals; Cell Movement; Cell Proliferation; Humans; Hy | 2017 |
Melatonin and Cancer Hallmarks.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Cell Transformation, Neoplastic; Disease Pr | 2018 |
Biliary epithelium: A neuroendocrine compartment in cholestatic liver disease.
Topics: Animals; Arginine Vasopressin; Biliary Tract; Cell Proliferation; Cholangitis; Cholestasis; Epitheli | 2018 |
Melatonin as a treatment for gastrointestinal cancer: a review.
Topics: Animals; Cell Proliferation; Drug Synergism; Gastrointestinal Neoplasms; Humans; Melatonin; Neovascu | 2015 |
Melatonin, an inhibitory agent in breast cancer.
Topics: Animals; Apoptosis; Aromatase; Breast Neoplasms; Estrogens; Female; Humans; Melatonin; Metabolic Net | 2017 |
23 other studies available for melatonin and Angiogenesis, Pathologic
| Article | Year |
|---|---|
Effect of Apatinib plus melatonin on vasculogenic mimicry formation by cancer stem cells from breast cancer cell line.
Topics: Breast Neoplasms; Cell Line, Tumor; Female; Humans; MCF-7 Cells; Melatonin; Neoplastic Stem Cells; N | 2022 |
Development of in vitro and in vivo tools to evaluate the antiangiogenic potential of melatonin to neutralize the angiogenic effects of VEGF and breast cancer cells: CAM assay and 3D endothelial cell spheroids.
Topics: Angiogenesis Inducing Agents; Angiogenesis Inhibitors; Animals; Chick Embryo; Chorioallantoic Membra | 2023 |
Development of in vitro and in vivo tools to evaluate the antiangiogenic potential of melatonin to neutralize the angiogenic effects of VEGF and breast cancer cells: CAM assay and 3D endothelial cell spheroids.
Topics: Angiogenesis Inducing Agents; Angiogenesis Inhibitors; Animals; Chick Embryo; Chorioallantoic Membra | 2023 |
Development of in vitro and in vivo tools to evaluate the antiangiogenic potential of melatonin to neutralize the angiogenic effects of VEGF and breast cancer cells: CAM assay and 3D endothelial cell spheroids.
Topics: Angiogenesis Inducing Agents; Angiogenesis Inhibitors; Animals; Chick Embryo; Chorioallantoic Membra | 2023 |
Development of in vitro and in vivo tools to evaluate the antiangiogenic potential of melatonin to neutralize the angiogenic effects of VEGF and breast cancer cells: CAM assay and 3D endothelial cell spheroids.
Topics: Angiogenesis Inducing Agents; Angiogenesis Inhibitors; Animals; Chick Embryo; Chorioallantoic Membra | 2023 |
Development of in vitro and in vivo tools to evaluate the antiangiogenic potential of melatonin to neutralize the angiogenic effects of VEGF and breast cancer cells: CAM assay and 3D endothelial cell spheroids.
Topics: Angiogenesis Inducing Agents; Angiogenesis Inhibitors; Animals; Chick Embryo; Chorioallantoic Membra | 2023 |
Development of in vitro and in vivo tools to evaluate the antiangiogenic potential of melatonin to neutralize the angiogenic effects of VEGF and breast cancer cells: CAM assay and 3D endothelial cell spheroids.
Topics: Angiogenesis Inducing Agents; Angiogenesis Inhibitors; Animals; Chick Embryo; Chorioallantoic Membra | 2023 |
Development of in vitro and in vivo tools to evaluate the antiangiogenic potential of melatonin to neutralize the angiogenic effects of VEGF and breast cancer cells: CAM assay and 3D endothelial cell spheroids.
Topics: Angiogenesis Inducing Agents; Angiogenesis Inhibitors; Animals; Chick Embryo; Chorioallantoic Membra | 2023 |
Development of in vitro and in vivo tools to evaluate the antiangiogenic potential of melatonin to neutralize the angiogenic effects of VEGF and breast cancer cells: CAM assay and 3D endothelial cell spheroids.
Topics: Angiogenesis Inducing Agents; Angiogenesis Inhibitors; Animals; Chick Embryo; Chorioallantoic Membra | 2023 |
Development of in vitro and in vivo tools to evaluate the antiangiogenic potential of melatonin to neutralize the angiogenic effects of VEGF and breast cancer cells: CAM assay and 3D endothelial cell spheroids.
Topics: Angiogenesis Inducing Agents; Angiogenesis Inhibitors; Animals; Chick Embryo; Chorioallantoic Membra | 2023 |
A ketogenic diet combined with melatonin overcomes cisplatin and vincristine drug resistance in breast carcinoma syngraft.
Topics: Animals; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Caspase 3; Cell Line, Tumor; Cisplatin; | 2020 |
Usefulness of melatonin as complementary to chemotherapeutic agents at different stages of the angiogenic process.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Docetaxel; Drug Synergism; Gene Expression; Human Um | 2020 |
Inhibitory effect of melatonin on hypoxia-induced vasculogenic mimicry via suppressing epithelial-mesenchymal transition (EMT) in breast cancer stem cells.
Topics: Angiogenic Proteins; Antineoplastic Agents; Breast Neoplasms; Cell Movement; Cell Proliferation; Dru | 2020 |
Melatonin regulates tumor angiogenesis via miR-424-5p/VEGFA signaling pathway in osteosarcoma.
Topics: Angiogenesis Inhibitors; Animals; Bone Neoplasms; Cell Line, Tumor; Chickens; Egg Yolk; Endothelial | 2020 |
Melatonin Reduces Angiogenesis in Serous Papillary Ovarian Carcinoma of Ethanol-Preferring Rats.
Topics: Alcohol Drinking; Animals; Antioxidants; Blotting, Western; Cystadenocarcinoma, Papillary; Cystadeno | 2017 |
Amelioration of Dalton's lymphoma-induced angiogenesis by melatonin.
Topics: Animals; Blood Vessels; Carcinogenesis; Cell Movement; Cell Proliferation; Disease Models, Animal; E | 2017 |
Efficacy of melatonin, IL-25 and siIL-17B in tumorigenesis-associated properties of breast cancer cell lines.
Topics: Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Female; Fluorescent Antibody Technique | 2017 |
Melatonin restrains angiogenic factors in triple-negative breast cancer by targeting miR-152-3p: In vivo and in vitro studies.
Topics: Angiogenesis Inducing Agents; Animals; Antioxidants; Apoptosis; Biomarkers, Tumor; Cell Proliferatio | 2018 |
Therapeutic Potential of Melatonin in the Regulation of MiR-148a-3p and Angiogenic Factors in Breast Cancer.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Movement; Cell Proliferation; Drug Screening | 2019 |
The Role of Melatonin in Oxidative Stress, DNA Damage, Apoptosis and Angiogenesis in Fetal Eye under Preeclampsia and Melatonin Deficiency Stress.
Topics: Animals; Apoptosis; Aryl Hydrocarbon Receptor Nuclear Translocator; Blotting, Western; DNA Damage; E | 2019 |
Inhibition of VEGF expression through blockade of Hif1α and STAT3 signalling mediates the anti-angiogenic effect of melatonin in HepG2 liver cancer cells.
Topics: Angiogenesis Inhibitors; Apoptosis; Carcinoma, Hepatocellular; Cell Hypoxia; Cobalt; Cyclic S-Oxides | 2013 |
Effect of melatonin on tumor growth and angiogenesis in xenograft model of breast cancer.
Topics: Animals; Antineoplastic Agents; Antioxidants; Breast Neoplasms; ErbB Receptors; Female; Gene Express | 2014 |
Molecular markers of angiogenesis and metastasis in lines of oral carcinoma after treatment with melatonin.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Cell Line, Tumor; Cell Survival; Gene Expression; Humans; | 2014 |
Melatonin Regulates Angiogenic Factors under Hypoxia in Breast Cancer Cell Lines.
Topics: Angiogenesis Inhibitors; Antioxidants; Breast Neoplasms; Cell Hypoxia; Cell Survival; Cytokines; Erb | 2016 |
Melatonin Regulates Angiogenic and Inflammatory Proteins in MDA-MB-231 Cell Line and in Co-culture with Cancer-associated Fibroblasts.
Topics: Cancer-Associated Fibroblasts; Cell Survival; Coculture Techniques; Humans; Inflammation; Melatonin; | 2016 |
Melatonin suppresses tumor angiogenesis by inhibiting HIF-1alpha stabilization under hypoxia.
Topics: Antioxidants; Cell Hypoxia; Cells, Cultured; Colonic Neoplasms; Culture Media, Conditioned; Humans; | 2010 |
Sphingosine kinase 1 pathway is involved in melatonin-induced HIF-1α inactivation in hypoxic PC-3 prostate cancer cells.
Topics: Cell Hypoxia; Cell Line, Tumor; Gene Expression; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; | 2011 |
[Role of polymeric nitric oxide in oncopathology].
Topics: Animals; Carcinogens; Cell Transformation, Neoplastic; Electromagnetic Fields; Humans; Melatonin; Ne | 2010 |
Melatonin prevents human pancreatic carcinoma cell PANC-1-induced human umbilical vein endothelial cell proliferation and migration by inhibiting vascular endothelial growth factor expression.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Cell Proliferation; Coculture Techniques; En | 2012 |
Melatonin suppresses tumor progression by reducing angiogenesis stimulated by HIF-1 in a mouse tumor model.
Topics: Animals; Cell Line, Tumor; Hypoxia-Inducible Factor 1, alpha Subunit; Kidney Neoplasms; Male; Melato | 2013 |
Ex vivo pretreatment with melatonin improves survival, proangiogenic/mitogenic activity, and efficiency of mesenchymal stem cells injected into ischemic kidney.
Topics: Animals; Bone Marrow Cells; Cell Proliferation; Cell Survival; Fibroblast Growth Factor 2; Hepatocyt | 2008 |